Audrene Rice, Our R&D Pipeline and Portfolio Manager, is attending  Bio-Europe from March 17-19 in Milan, Italy

Now approved for use in Pediatrics

• Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
• Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.